4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Solid Biosciences Inc. (SLDB) operates in the Biotechnology industry and is headquartered in Charlestown, United States with about 121 employees. Its market capitalization is roughly $1 billion. In the fiscal year ended 2025-12-31, SLDB reported $0M in revenue and ($174M) in net income.
Solid Biosciences Inc. develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, which is in phase 1/2 for the treatment of Duchenne muscular dystrophy.
Interactive charts & full statements →
| Income statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $8M | — |
| Operating Income (EBIT) | ($179M) | ($130M) | ($104M) | ($99M) | — |
| Net Income | ($174M) | ($125M) | ($96M) | ($86M) | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M | $0M | — |
| Operating Income (EBIT) | ($57M) | ($49M) | ($48M) | ($42M) | ($40M) | — |
| Net Income | ($57M) | ($50M) | ($46M) | ($40M) | ($39M) | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Assets | $232M | $189M | $165M | $260M | — |
| Total Liabilities | $52M | $51M | $38M | $49M | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive SLDB viewer.
About TickerBase · Data methodology & sources